WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) and HEALWELL AI Inc. (TSX: AIDX) announced on October 28, 2026 that Canada's Competition Bureau has concluded its merger review and issued a No Action Letter regarding WELL's acquisition of a controlling interest in HEALWELL. The letter, issued October 22, 2026, confirms the Commissioner of Competition does not intend to challenge the transaction under section 92 of the Competition Act. The regulatory clearance removes a material overhang on WELL's strategy to expand its artificial intelligence and digital health capabilities through HEALWELL.

Key Points

  • WELL Health Technologies Corp. (TSX: WELL) and HEALWELL AI Inc. (TSX: AIDX) received regulatory clearance from Canada's Competition Bureau
  • The Competition Bureau issued a No Action Letter on October 22, 2026, concluding its merger review
  • The review covered WELL's acquisition of a controlling interest in HEALWELL completed April 1, 2025, including HEALWELL's concurrent acquisition of Orion Health
  • Investors may watch for updates on WELL's integration of HEALWELL's AI-driven preventative care capabilities into its broader platform

Competition Bureau No Action Letter Clears WELL–HEALWELL Transaction

The No Action Letter, dated October 22, 2026, confirms that the Commissioner of Competition does not currently intend to apply under section 92 of the Competition Act to challenge WELL's acquisition of a majority interest in HEALWELL. The transaction reviewed includes HEALWELL's concurrent acquisition of Orion Health and was originally completed on April 1, 2025. The Bureau's conclusion marks the formal end of its regulatory scrutiny of a deal that combined two publicly traded Canadian digital health and AI companies.

Federal Court Records Order and Cooperative Review Process

In December 2025, the Competition Bureau announced it had obtained a Federal Court order for the production of records and information related to the transaction. The announcement states that both WELL and HEALWELL cooperated fully with the Bureau throughout its review and supplied all records and information requested. The disclosure suggests the review was thorough, spanning several months and involving formal court-ordered document production before the Commissioner determined no further action was warranted.

CEO Hamed Shahbazi Signals Focus on Execution and Shareholder Value

In a statement included in the announcement, WELL Founder, Chairman, and CEO Hamed Shahbazi expressed satisfaction with the Bureau's conclusion, noting the company appreciates the Bureau's engagement and remains focused on executing its strategy. Shahbazi indicated the company's priorities centre on delivering value to healthcare practitioners, patients, and shareholders. The immediate share price impact was not clear from available public information at time of publication.

WELL's Scale in Canadian Digital Healthcare

WELL describes itself as Canada's largest outpatient healthcare company, operating 275 clinics and supporting more than 5 million annual patient visits. Through its WELLSTAR subsidiary, it provides electronic medical records and AI-powered clinical tools. HEALWELL focuses on preventative care, AI-powered patient identification, and clinical decision support. Together, the combined entity positions WELL to expand AI integration across its clinical network, though specific integration milestones were not disclosed in this announcement.